BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease** Shares of developer Roivant ROIV.O up 8.8% at $23 premarket
** Co says in a mid‑stage trial, brepocitinib improved symptoms of cutaneous sarcoidosis — a rare skin disease caused by inflammation that forms painful lumps under the skin
** Higher dose improved disease activity scores by about 22 points over 16 weeks vs about 1 point for placebo, co says
** More than half of treated patients reached functional remission, per investigator Dr. Misha Rosenbach
** Co to start late-stage trial in 2026 after talks with U.S. FDA
** Shares up ~83% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments